05 Jun Financing Maternal RSV Immunization Through Reduced-Dose PCV Schedules
Pneumonia remains the leading infectious cause of death among children under five, accounting for more than 600,000 deaths annually worldwide. Despite gains in vaccine coverage, progress reducing pneumonia deaths has slowed, and many countries face increasingly constrained health budgets. At the same time, new tools are becoming available that could substantially reduce child mortality from respiratory infections. The challenge is how to finance them.
A potentially transformative opportunity exists to reduce child pneumonia deaths with limited increases in immunization budgets. Countries with sustained high coverage of three-dose infant pneumococcal conjugate vaccine (PCV) schedules could consider reducing to a two-dose schedule and reinvesting the resulting savings into maternal respiratory syncytial virus (RSV) vaccination. Such a strategy could increase overall protection against severe childhood respiratory disease with minimal additional costs, and potentially even cost savings when reductions in RSV hospitalizations are taken into account.
This possibility arises because the global epidemiology of pneumococcal disease has changed substantially since PCV introduction. Following widespread vaccination, vaccine-type pneumococcal carriage and disease have declined dramatically in many settings. Direct protection has been supplemented by strong indirect effects, reducing transmission across age groups and lowering disease incidence even among unvaccinated populations.
Evidence from immunogenicity studies, surveillance programs, and transmission models suggests that in settings with high vaccine coverage and mature programs, fewer PCV doses may maintain most of the population-level benefits achieved by more intensive schedules. But so far, the United Kingdom is the only country to move to a two-dose PCV schedule, with impressive results.
The financial implications of this move are substantial. PCV remains one of the most expensive childhood vaccines. Depending on procurement arrangements, vaccine prices, and birth cohort size, eliminating a single infant dose can generate savings equivalent to 20–35% of total PCV program costs.
For illustration, a country with one million annual births and 90% coverage currently administering three doses delivers approximately 2.7 million PCV doses each year. Reducing the schedule by one dose would eliminate roughly 900,000 doses annually. At a vaccine and delivery cost of US$3–7 per dose, this represents savings of approximately US$3–6 million per year. In larger middle-income countries, annual savings could exceed US$10 million.
These resources could potentially finance maternal RSV immunization, especially in the countries supported by Gavi, the Vaccine Alliance where a very low price for the RSV maternal vaccine has been negotiated.
RSV is responsible for an estimated 33 million episodes of acute lower respiratory infection annually among young children worldwide and remains one of the leading causes of infant hospitalization. Recent estimates suggest that RSV causes more than 100,000 child deaths annually, with deaths concentrated in the first six months of life in low-income settings where access to supportive care is limited.
The recent development of maternal RSV vaccines has fundamentally changed prevention options. Administered during late pregnancy, a single maternal dose provides passive protection through transplacental antibody transfer during the period when infants face the highest risk of severe disease and death. Clinical trial data suggest protection against severe RSV-associated lower respiratory tract disease of approximately 70–80% during the first months of life, precisely when mortality risk is greatest.
From a program perspective, maternal RSV vaccination offers several advantages. It requires only a single dose, can be delivered through existing antenatal care services, and protects infants from birth. In contrast to infant vaccination programs, maternal immunization does not require additional postnatal contacts or expansion of infant vaccination schedules.
The central policy question for many countries is therefore not whether a three-dose PCV schedule is marginally better than a two-dose schedule, but whether the health gains associated with the third PCV dose exceed the gains achievable through alternative uses of the same resources.
Health-economics suggests that the answer may increasingly favor reinvestment. In populations with high PCV coverage and strong herd protection, the incremental benefit of the final dose may be relatively small because most vaccine-preventable diseases have already been eliminated. Meanwhile, maternal RSV vaccination targets a major remaining cause of severe infant pneumonia for which population immunity remains limited.
Simple modeling illustrates the potential. Consider a Gavi-eligible country with one million births annually. If reducing PCV by one dose generated US$5 million in annual savings and maternal RSV vaccination cost approximately US$5–6 per pregnant woman vaccinated, those savings could finance vaccination of roughly 800,000–1,000,000 pregnant women each year. Assuming 60–70% coverage and effectiveness estimates consistent with phase III trial data, thousands of RSV-associated hospitalizations and hundreds of severe disease episodes could be prevented annually.
Even if reduced-dose PCV schedules resulted in a small increase in residual pneumococcal disease, the overall balance of health benefits could remain strongly positive. Because RSV burden is concentrated in the youngest infants—the age group at highest risk of death—the mortality impact per vaccine dose may be particularly favorable.
Importantly, this argument is not that all countries should immediately reduce PCV schedules. Decisions must remain evidence-based and context-specific. Countries with low PCV coverage, persistent vaccine-type circulation, weak surveillance systems, or substantial residual pneumococcal disease may appropriately retain existing schedules. Similarly, the affordability of maternal RSV vaccination will depend on negotiated product prices and procurement mechanisms.
However, the possibility deserves rigorous investigation. National immunization Technical Advisory Groups (NITAGs), Ministries of Health, Gavi, vaccine manufacturers, and global health agencies should evaluate integrated scenarios rather than considering each vaccine independently. Dynamic transmission models, budget-impact analyses, and cost-effectiveness studies should compare current programs with alternatives that combine reduced-dose PCV schedules and maternal RSV immunization.
Such analyses should focus on outcomes that matter most to policymakers: deaths averted, hospitalizations prevented, program affordability, and financial sustainability. The relevant objective is not to maximize protection against any single pathogen but to maximize child survival within constrained budgets.
More broadly, this proposal highlights an emerging challenge for immunization programs. As new vaccines become available, countries cannot simply continue adding products without reassessing existing investments. The future of immunization policy will increasingly depend on optimization rather than expansion alone. Mature vaccine programs should periodically be re-evaluated in light of changing epidemiology, evolving evidence, and new prevention opportunities.
The emergence of maternal RSV vaccination coincides with a moment when many PCV programs are reaching maturity. Together, these developments create a rare opportunity to improve efficiency and health impact simultaneously. Reinvesting savings from reduced-dose PCV schedules into maternal RSV immunization could allow some countries to prevent more childhood pneumonia deaths without increasing expenditure.
At a time when global health resources are under pressure and child mortality reduction is slowing, opportunities of this kind deserve urgent attention. While it may not be possible for many countries to spend more on immunization, they can obtain greater health gains from the resources already available. For many countries, the combination of reduced-dose PCV schedules and maternal RSV vaccination may offer exactly that possibility. In fact, it may be the only way that the RSV maternal vaccine can be introduced in the countries where child pneumonia deaths are concentrated in the immediate future.
June 2026